F
FIBROBIOLOGICS, INC. COMMON STOCK
NASDAQ: FBLG (FibroBiologics, Inc.)
最近更新时间: 1小时之前0.980
0.02 (2.06%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | FibroBiologics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | -4.4 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -4.4 |
| 时机 35% | -0.5 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | 2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -36.3% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | 0.1 |
| 最终评分 | -2.60 |
|
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 21.42% |
| 机构持股比例 | 16.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cascade Financial Partners, Llc | 30 Jun 2026 | 108,828 |
| Ifp Advisors, Inc | 30 Sep 2026 | 27,000 |
| Qube Research & Technologies Ltd | 30 Jun 2026 | 24,313 |
| Grove Bank & Trust | 30 Sep 2026 | 100 |
| Bfc Planning, Inc. | 30 Jun 2026 | 50 |
该时间范围内无数据。
投资组合